as 10-28-2025 1:57am EST
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
| Founded: | 1949 | Country: | Ireland |
| Employees: | N/A | City: | GALWAY |
| Market Cap: | 114.9B | IPO Year: | N/A |
| Target Price: | $104.07 | AVG Volume (30 days): | 6.5M |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 3.62 | EPS Growth: | 21.95 |
| 52 Week Low/High: | $79.29 - $99.37 | Next Earning Date: | 11-18-2025 |
| Revenue: | $34,200,000,000 | Revenue Growth: | 4.98% |
| Revenue Growth (this year): | 7.97% | Revenue Growth (next year): | 5.47% |
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| KIIL HARRY SKIP | MDT | EVP & President Cardiovascular | Sep 3 '25 | Sell | $91.59 | 8,605 | $788,047.90 | 35,815 | |
| Jellison William R | MDT | N/A | Aug 25 '25 | Buy | $92.37 | 2,500 | $230,925.00 | 5,000 | |
| Jellison William R | MDT | N/A | Aug 22 '25 | Buy | $92.73 | 2,500 | $231,825.00 | 5,000 |
MDT Breaking Stock News: Dive into MDT Ticker-Specific Updates for Smart Investing
Barchart
16 hours ago
Motley Fool
18 hours ago
GlobeNewswire
19 hours ago
Motley Fool
19 hours ago
MT Newswires
a day ago
PR Newswire
a day ago
Motley Fool
2 days ago
Motley Fool
2 days ago
The information presented on this page, "MDT Medtronic plc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.